AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39703564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dose-dense epirubicin/cyclophosphamide (EC) and docetaxel (D)
Number of subjects: 2003
Study 39703741 — intervention group
Group type: EXPERIMENTAL
Intervention: sTULSA
Number of subjects: 39
Study 39703879 — intervention group
Group type: EXPERIMENTAL
Intervention: Early standardized educational protocol provided from 42 to 48 months of age
Number of subjects: 552
Study 39703879 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 552
Study 39703883 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR) using Prizvalve
Number of subjects: 5
Study 39703895 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-duty interventions (DDIs)
Number of subjects: 708
Study 39703895 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 708
Study 39704038 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone preoperative video education
Number of subjects: 677
Study 39704038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined video education (Video & Anaesthesiologist)
Number of subjects: 677
Study 39704038 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face education by an anaesthesiologist
Number of subjects: 677
Study 39704053 — intervention group
Group type: COMPARATOR
Intervention: CACS of 0
Number of subjects: 460
Study 39704053 — intervention group
Group type: EXPERIMENTAL
Intervention: CACS >0 (combined groups of 1 to 99, 100 to 399, 400 to 999, and ≥1000)
Number of subjects: 460
Study 39704053 — intervention group
Group type: EXPERIMENTAL
Intervention: CACS >0 (combined groups)
Number of subjects: 460
Study 39704055 — intervention group
Group type: COMPARATOR
Intervention: Single-SR
Number of subjects: 108
Study 39704055 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-SR
Number of subjects: 108
Study 39704175 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-5190457 100mg b.i.d.
Number of subjects: 42
Study 39704175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 39704211 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based lifestyle intervention program targeting diet and physical activity
Number of subjects: 57210
Study 39704227 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI class B/C
Number of subjects: 789
Study 39704227 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI class D
Number of subjects: 789
Study 39704227 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAI class E
Number of subjects: 789
Study 39704257 — intervention group
Group type: EXPERIMENTAL
Intervention: Men diagnosed with IC/BPS
Number of subjects: 961
Study 39704257 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with IC/BPS
Number of subjects: 961
Study 39704257 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with CP/CPPS only
Number of subjects: 961
Study 39704257 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 961
Study 39704257 — intervention group
Group type: EXPERIMENTAL
Intervention: Men and women
Number of subjects: 961
Study 39704257 — intervention group
Group type: EXPERIMENTAL
Intervention: Women compared to men
Number of subjects: 961
Study 39704322 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ordinated training (body movements with concurrent pelvic floor muscle contraction)
Number of subjects: 4920
Study 39704322 — intervention group
Group type: COMPARATOR
Intervention: Direct PFMT (sets of repeated, isolated, voluntary pelvic floor muscle contractions)
Number of subjects: 4920
Study 39704322 — intervention group
Group type: COMPARATOR
Intervention: Supervised PFMT (individually or in a group)
Number of subjects: 4920
Study 39704778 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% APRP
Number of subjects: 96
Study 39704778 — intervention group
Group type: COMPARATOR
Intervention: 100% AS
Number of subjects: 96
Study 39705091 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0
Study 39705091 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0
Study 39705091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 39705212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-lead ECG device for 1 year after PVI
Number of subjects: 204
Study 39705212 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no 1-lead ECG device)
Number of subjects: 204
Study 39705390 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Number of subjects: 6100
Study 39705390 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 6100
Study 39705540 — intervention group
Group type: EXPERIMENTAL
Intervention: Voruciclib (initially 100 mg daily continuously on a 28-day cycle, then changed to days 1-14 of a 28-day cycle); dose escalation stopped at 200 mg.
Number of subjects: 40
Study 39705540 — intervention group
Group type: EXPERIMENTAL
Intervention: Voruciclib (200 mg on days 1-14 of a 28-day cycle);
Number of subjects: 40
Study 39705540 — intervention group
Group type: EXPERIMENTAL
Intervention: Voruciclib;
Number of subjects: 40
Study 39705576 — intervention group
Group type: EXPERIMENTAL
Intervention: PCa-SCP intervention
Number of subjects: 189
Study 39705576 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study 39705631 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alteplase
Number of subjects: 185
Study 39705631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 39705694 — intervention group
Group type: EXPERIMENTAL
Intervention: Verily Study Watch (VSW) RHR measurement
Number of subjects: 875
Study 39705738 — intervention group
Group type: EXPERIMENTAL
Intervention: VVZ-149 (n = 141)
Number of subjects: 284
Study 39705738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 143)
Number of subjects: 284
Study 39705739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation during general anesthesia with low end-tidal CO2 (etCO2)
Number of subjects: 1843
Study 39705739 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1843
Study 39705855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC)
Number of subjects: 174
Study 39705855 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine
Number of subjects: 174
Study 39705855 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin (3rd-hour)
Number of subjects: 174
Study 39706105 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal attainment theory-based intervention
Number of subjects: 157
Study 39706105 — intervention group
Group type: COMPARATOR
Intervention: Routine health education (Control)
Number of subjects: 157
Study 39706212 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 2×10^6 allogeneic umbilical cord-derived mesenchymal stromal cells
Number of subjects: 8
Study 39706212 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 39706209 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg given intravenously at weeks 0, 4, and 8 (induction)
Number of subjects: 701
Study 39706209 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg given subcutaneously every 4 weeks (maintenance)
Number of subjects: 701
Study 39706209 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg given subcutaneously every 8 weeks (maintenance)
Number of subjects: 701
Study 39706209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (induction)
Number of subjects: 701
Study 39706209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maintenance)
Number of subjects: 701
Study 39706330 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Adolescent Community Reinforcement Approach (E-ACRA)
Number of subjects: 0
Study 39706330 — intervention group
Group type: COMPARATOR
Intervention: Assertive Community Support (ACS)
Number of subjects: 0
Study 39706330 — intervention group
Group type: EXPERIMENTAL
Intervention: E-ACRA
Number of subjects: 0
Study 39706330 — intervention group
Group type: COMPARATOR
Intervention: ACS
Number of subjects: 0
Study 39706335 — intervention group
Group type: EXPERIMENTAL
Intervention: avelumab + axitinib
Number of subjects: 0
Study 39706335 — intervention group
Group type: COMPARATOR
Intervention: sunitinib
Number of subjects: 0
Study 39706483 — intervention group
Group type: EXPERIMENTAL
Intervention: tPBM
Number of subjects: 48
Study 39706483 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 48
Study 39706632 — intervention group
Group type: EXPERIMENTAL
Intervention: NG101 (45 mg intrathecal injections, 6 doses every 5 days over 4 weeks)
Number of subjects: 129
Study 39706632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (phosphate-buffered saline)
Number of subjects: 129
Study 39706632 — intervention group
Group type: EXPERIMENTAL
Intervention: NG101
Number of subjects: 129
Study 39706632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 39706650 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Mobilisation and Incentivisation
Number of subjects: 21638
Study 39706650 — intervention group
Group type: COMPARATOR
Intervention: Community Mobilisation
Number of subjects: 21638
Study 39706666 — intervention group
Group type: EXPERIMENTAL
Intervention: TdaP vaccine
Number of subjects: 181
Study 39706666 — intervention group
Group type: COMPARATOR
Intervention: Td vaccine
Number of subjects: 181
Study 39706691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear aligner (CA)
Number of subjects: 24
Study 39706691 — intervention group
Group type: COMPARATOR
Intervention: Removable inclined plane (RIP)
Number of subjects: 24
Study 39706761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF) fixed dosing (45/200 mg)
Number of subjects: 22
Study 39706761 — intervention group
Group type: EXPERIMENTAL
Intervention: Population PK modeling
Number of subjects: 22
Study 39706803 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE (group psychosocial telehealth intervention)
Number of subjects: 100
Study 39706803 — intervention group
Group type: COMPARATOR
Intervention: Medication monitoring (control group)
Number of subjects: 100
Study 39706874 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 640
Study 39706874 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle intervention
Number of subjects: 640
Study 39706874 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 640
Study 39706874 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 640
Study 39706981 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 101
Study 39706981 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 101
Study 39707032 — intervention group
Group type: EXPERIMENTAL
Intervention: AIIR (grades 1-5)
Number of subjects: 62
Study 39707032 — intervention group
Group type: COMPARATOR
Intervention: AIIR (grades 3 and 5)
Number of subjects: 62
Study 39707032 — intervention group
Group type: COMPARATOR
Intervention: SDCT (Karl 3D-5)
Number of subjects: 62
Study 39707032 — intervention group
Group type: COMPARATOR
Intervention: LDCT (Karl 3D-5 and AIIR-3 and 5)
Number of subjects: 62
Study 39707042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 3481
Study 39707042 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 3481
Study 39707042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (3rd-line)
Number of subjects: 3481
Study 39707077 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 1800 mg intravenous infusion once every 4 weeks for four doses
Number of subjects: 20
Study 39707126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-phase cone-beam CT (CBCT)
Number of subjects: 30
Study 39707126 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment contrast-enhanced CT (CECT)
Number of subjects: 30
Study 39707137 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT), administered once every other day for 30 min per session, totaling 14 sessions over 4 weeks
Number of subjects: 31
Study 39707137 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs), no SMT treatment
Number of subjects: 31
Study 39707138 — intervention group
Group type: EXPERIMENTAL
Intervention: Juan Bi Pill (JBP) combined with Methotrexate (MTX, 10 mg per week)
Number of subjects: 115
Study 39707138 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with Methotrexate (MTX, 10 mg per week)
Number of subjects: 115
Study 39707158 — intervention group
Group type: COMPARATOR
Intervention: Dulce Digital (DD)
Number of subjects: 310
Study 39707158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulce Digital-Me (DD-Me-Auto)
Number of subjects: 310
Study 39707158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulce Digital-Me (DD-Me-Tel)
Number of subjects: 310
Study 39707209 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal oxygen therapy (target SpO2 of ≥ 96%)
Number of subjects: 106
Study 39707209 — intervention group
Group type: COMPARATOR
Intervention: Conservative oxygen therapy (target SpO2 of 88-92%)
Number of subjects: 106
Study 39707229 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0
Study 39707229 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 39707229 — intervention group
Group type: EXPERIMENTAL
Intervention: ITT analysis of brigatinib
Number of subjects: 0
Study 39707239 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug tapering and treatment for underlying psychiatric disorders
Number of subjects: 405
Study 39707275 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign hysterectomy
Number of subjects: 440
Study 39707277 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 30
Study 39707277 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 30
Study 39707277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diet and exercise intervention
Number of subjects: 30
Study 39707277 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 39707287 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Break intervention (AB-group)
Number of subjects: 50
Study 39707287 — intervention group
Group type: COMPARATOR
Intervention: Self-administered care recommendations (C-group)
Number of subjects: 50
Study 39707376 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 190
Study 39707376 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 190
Study 39707385 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist vibratory reminders during a six-week home-based intervention
Number of subjects: 42
Study 39707385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 42
Study 39707385 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist vibratory reminders during a six-week home-based intervention (for participants with sufficient sensor data)
Number of subjects: 42
Study 39707385 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial impairment level
Number of subjects: 42
Study 39707407 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative methadone (0.10 mg/kg, administered intravenously at anesthesia induction)
Number of subjects: 130
Study 39707407 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 130
Study 39707407 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative methadone
Number of subjects: 130
Study 39707490 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-positive-at-admission (PA-ESBL) patients
Number of subjects: 3703
Study 39707490 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-negative-at-admission (NA-ESBL) patients
Number of subjects: 3703
Study 39707490 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving antibiotics
Number of subjects: 3703
Study 39707490 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous infections
Number of subjects: 3703
Study 39707490 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct between-patients transmission clusters
Number of subjects: 3703
Study 39707531 — intervention group
Group type: EXPERIMENTAL
Intervention: Critically short telomeres (%CST)
Number of subjects: 129
Study 39707531 — intervention group
Group type: EXPERIMENTAL
Intervention: Critically short telomeres (%CST) in APOE4 carriers
Number of subjects: 129
Study 39707544 — intervention group
Group type: EXPERIMENTAL
Intervention: Males who showed interest in the trial
Number of subjects: 0
Study 39707544 — intervention group
Group type: COMPARATOR
Intervention: Males attending an in-person information session
Number of subjects: 0
Study 39707544 — intervention group
Group type: COMPARATOR
Intervention: Females attending an in-person information session
Number of subjects: 0
Study 39707544 — intervention group
Group type: EXPERIMENTAL
Intervention: Males and females who demonstrated initial interest
Number of subjects: 0
Study 39707595 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + ET (PALBO)
Number of subjects: 623
Study 39707595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib + ET (RIBO)
Number of subjects: 623
Study 39707865 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% fish oil lipid emulsion (FOLE) 1 g/kg
Number of subjects: 0
Study 39707865 — intervention group
Group type: COMPARATOR
Intervention: 100% soybean oil lipid emulsion (SOLE) 1.9 g/kg
Number of subjects: 0
Study 39708027 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDD <55 mm
Number of subjects: 1921
Study 39708035 — intervention group
Group type: EXPERIMENTAL
Intervention: HPSD 70 W/9-10 s
Number of subjects: 304
Study 39708035 — intervention group
Group type: COMPARATOR
Intervention: CPD 25-40 W
Number of subjects: 304
Study 39708049 — intervention group
Group type: EXPERIMENTAL
Intervention: Popliteal vein functional diameter measurement before and after compression with thigh inflatable cuff
Number of subjects: 173
Study 39708052 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxin withdrawal in mice for 1 or 2 weeks
Number of subjects: 128
Study 39708052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged abstinence in patients with alcohol-related cirrhosis
Number of subjects: 128
Study 39708052 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent hepatic proinflammatory environment in regressive mice
Number of subjects: 128
Study 39708052 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CRP, IL-6, IgA, and IgG levels in abstinent patients
Number of subjects: 128
Study 39708086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2G oral semaglutide (9 mg)
Number of subjects: 222
Study 39708086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2G oral semaglutide (4 mg)
Number of subjects: 222
Study 39708086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2G oral semaglutide (1.5 mg)
Number of subjects: 222
Study 39708086 — intervention group
Group type: COMPARATOR
Intervention: 2G oral semaglutide
Number of subjects: 222
Study 39708224 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing from a Registered Dietitian (RDMI) during a 6-month intensive Food is Medicine (FIM) intervention
Number of subjects: 85
Study 39708245 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-high-power short-duration (vHPSD) radiofrequency ablation (90 W, 4 s)
Number of subjects: 2
Study 39708245 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (25-40 W applications, unlimited duration)
Number of subjects: 2
Study 39708245 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-high-power short-duration (vHPSD) radiofrequency ablation
Number of subjects: 2
Study 39708253 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial nephrectomy (PN)
Number of subjects: 20523
Study 39708253 — intervention group
Group type: EXPERIMENTAL
Intervention: Local tumor destruction (LTD)
Number of subjects: 20523
Study 39708253 — intervention group
Group type: COMPARATOR
Intervention: Synchronous BRCC
Number of subjects: 20523
Study 39708253 — intervention group
Group type: COMPARATOR
Intervention: Metachronous BRCC
Number of subjects: 20523
Study 39708253 — intervention group
Group type: COMPARATOR
Intervention: Radical nephrectomy
Number of subjects: 20523
Study 39708367 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 120
Study 39708367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 39708367 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 120
Study 39708369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ruxolitinib 1.5% cream applied twice daily for 16 weeks
Number of subjects: 6
Study 39708369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ruxolitinib treatment
Number of subjects: 6
Study 39708537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin (PITHAC) with doses of 7.5-12.5-35-70 mg/m2 heated at 39±1 °C
Number of subjects: 15
Study 39708826 — intervention group
Group type: EXPERIMENTAL
Intervention: LVA therapy (2 g amoxicillin: 1 g twice a day)
Number of subjects: 504
Study 39708826 — intervention group
Group type: EXPERIMENTAL
Intervention: HVA therapy (3 g amoxicillin: 1 g three times a day)
Number of subjects: 504
Study 39708826 — intervention group
Group type: COMPARATOR
Intervention: LVA therapy
Number of subjects: 504
Study 39708826 — intervention group
Group type: COMPARATOR
Intervention: HVA therapy
Number of subjects: 504
Study 39708824 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV533
Number of subjects: 69
Study 39708824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 39708824 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV533 (fasted)
Number of subjects: 69
Study 39708824 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV533 (fed)
Number of subjects: 69
Study 39708824 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV533 (after high-fat meal)
Number of subjects: 69
Study 39709140 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC88473 (30.6 mg)
Number of subjects: 60
Study 39709140 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC88473 (68.0 mg)
Number of subjects: 60
Study 39709140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60